Baculovirus Expression System Market Size to Reach USD 707.0 Million in 2032
The Baculovirus Expression System Market size was USD 355.7 Million in 2024 and is expected to register a revenue CAGR of 8.9% during the forecast period
April 15, 2025 – Advancements in genetic engineering and biotechnology is a key driver driving baculovirus expression system market revenue growth. The BEVS, a flexible platform that has revolutionized recombinant protein synthesis, is essential for protein expression and biomanufacturing. Its unique ability to express target proteins at large levels makes it significant. The BEVS, due to its limited ability to replicate in mammalian cells, shields protein expression from viral activity. The safety feature makes it ideal for applications with stringent regulatory requirements.
The technology is scalable for both large-scale industrial biomanufacturing and small-scale laboratory investigations. Baculovirus-derived vector lent polymers (VLPs) are promising vaccination candidates that improve immunity. The system’s ability to express VLPs for influenza and human papillomavirus highlights its versatility in vaccine manufacturing.
On October 2023, Expression Systems, an Advancion firm, has launched a new, chemically defined insect cell culture medium that provides remarkable performance while enhancing the consistency and efficiency of gene therapy and other biologics production processes. ESF AdvanCD chemically defined insect cell culture medium is a unique formulation created exclusively by Expression Systems, a global leader in specialist cell culture media formulations, cell lines, and contract services for the baculovirus expression platform. The ESF AdvanCD cell culture medium allows for scaled baculovirus infection and protein expression in Spodoptera and Trichoplusia cell lines.
Despite having greater capacity than other viral vectors, baculovirus vectors have inherent constraints on DNA fragment size. This constraint can make it difficult to express multiple genes in a single construct, especially with baculovirus strains with restricted packaging capabilities. Hazardous proteins in insect cells may also affect BEVS-based protein synthesis. Certain proteins may naturally poison insect cells, reducing or killing them. This toxicity can make protein expression harder and reduce recombinant protein production.
Key Highlights:
- Baculovirus vectors segment is expected to register the largest market share over the forecast period. BEVS is recommended by researchers working with several protein targets due to its ability to alleviate problems with other expression methods. It is scalable, which makes it ideal for large-scale biomanufacturing. This enables protein production to expand smoothly to meet industrial demands. Baculoviruses have large genomes and sophisticated transfer vectors, making them easier to control. These features allow for accurate cloning and alteration of foreign genes in the viral genome, as well as straightforward insertion of large or multiple target genes.
- Recombinant protein production segment is expected to account for the highest growth rate over the forecast period. The baculovirus-insect cell expression system is a potent and versatile platform for creating a diverse spectrum of proteins, with significant benefits over other expression systems. Insect cells employed in the baculovirus-insect cell expression method are highly capable of performing a variety of post-translational modifications (PTMs), including glycosylation and acetylation. These PTMs are required to ensure correct protein folding, increased stability, and biological activity of the produced proteins. As a result, insect cells can generate proteins with complicated structures like those produced by mammalian cell culture.
- North America accounted for the largest market revenue share in the baculovirus expression system market in 2024 due to the advancements in genetic engineering and biotechnology and increasing adoption in drug discovery and structural biology. On August 2023, Profacgen, a prominent biotechnology company that delivers first-class protein expression services, has announced the launching of a multi-protein expression service in insect cells to assist scientists in protein co-expression network research and interaction studies. During high-level expression, this system is naturally safe and has post-translational modification capabilities comparable to mammalian cells. As a result, an increasing number of researchers prefer to use BEVS for protein co-expression studies in insect cells.
- Some major companies in the market report include Expression Systems, LLC, Takara Bio Inc., Sino Biological, Inc., GenScript Biotech Corporation, Thermo Fisher Scientific Inc., Merck KGaA, CUSABIO TECHNOLOGY LLC, Creative Biolabs Inc., ProMab Biotechnologies, Inc., KEMP PROTEINS, LLC., VWR International, LLC, Curia Global, Inc., Lifeasible, Biologics International Corp, and Gene Universal.
- On July 2024, Olon Group has announced the acquisition of GTP Bioways Group. GTP Bioways Group’s services are fully integrated with those of the Olon Biotech division. Olon Biotech’s technology solutions will be expanded and diversified because of this combination, which will support every stage of the lifecycle, from R&D and preclinical phases to manufacturing via microbial and mammalian fermentation and biotherapeutics. Olon Biotech will also offer comprehensive services for the development and manufacture of unique ADC classes, including mAbs, linkers, payloads, conjugation, and fill-and-finish processes.
Unlock the key to transforming your business strategy with our Baculovirus Expression System Market insights:
Navistrat Analytics has segmented Baculovirus Expression System market based on product type, application, and end-use:
- Product Type Outlook (Revenue, USD Million; 2022-2032)
- Baculovirus Vectors
- Expression Kits & Reagents
- Plasmids
- Transfection Reagents
- Buffers
- Cell Lines
- Instruments & Consumables
- Application Outlook (Revenue, USD Million; 2022-2032)
- Recombinant Protein Production
- Therapeutic Proteins & Vaccines
- Enzymes & Industrial Proteins
- Antibodies & Cytokines
- Gene Therapy & Viral Vector Production
- Cell-based Assays & Drug Discovery
- Structural Biology & Protein Interaction Studies
- Recombinant Protein Production
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs) & Contract Development & Manufacturing Organizations (CDMOs)
- Academic & Research Institutes
- Diagnostics & Vaccine Development Centers
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America